Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
BioNTech SE(BNTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BNTX
09/25/2026: BNTX (1-star) is currently NOT-A-BUY. Pass it for now.
BioNTech SE is a biotechnology company focused on developing personalized immunotherapies, most notably through its validated mRNA platform. While the company achieved historic financial success due to the global rollout of its COVID-19 vaccine, it is currently in a transition phase. The primary investment story rests on its pipeline of oncology candidates, which could unlock significant future value. However, investors face high execution and clinical trial risks, alongside intense competition from both large pharmaceutical firms and biotech peers. The stock is best suited for growth-oriented investors with a high risk tolerance who are monitoring clinical trial data as the key driver of long-term development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential linked to its mRNA pipeline and innovation. |
| Momentum investor | Mixed fit | Momentum depends heavily on clinical trial news and is conditional on positive market signals. |
| Value investor | Weak fit | The company's valuation is tied to future pipeline potential rather than current earnings. |
| Dividend investor | Weak fit | BioNTech does not pay dividends, as it focuses entirely on reinvestment. |
| Low-risk investor | Weak fit | Biotech stocks are inherently volatile due to clinical and regulatory uncertainties. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to news regarding clinical trials and pandemic-era revenue trends. |
| Valuation risk | Medium / high | Current valuations are speculative, relying on the future success of cancer therapies. |
| Competition risk (mRNA and Oncology) | High | Large-cap firms and peers like Moderna pose significant competitive threats to pipeline development. |
| Business quality | Medium | While the platform technology is strong, the transition from a single-product success is ongoing. |
| Dividend income | Low / none | Investors should not expect income as capital is reserved for operations. |
| Execution risk | High | Translating promising early data into approved oncology products is historically difficult. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -41.33% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.93B USD | Price to earnings Ratio - | 1Y Target Price 117.24 |
Price to earnings Ratio - | 1Y Target Price 117.24 | ||
Volume (30-day avg) 1.4M shares | Beta 1.29 | 52 Weeks Range 79.52 - 124.00 | Updated Date 09/25/2026 |
52 Weeks Range 79.52 - 124.00 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.75 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| COVID-19 Vaccine (Comirnaty) | Global sales and royalties from the mRNA vaccine. | The main historical revenue source, currently experiencing lower demand. |
| Collaborations and R&D | Upfront and milestone payments from pharma partners. | Revenue from partners who license or co-develop BioNTech's technology. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 8.18B | Price to Sales(TTM) 9.41 |
Enterprise Value 8.18B | Price to Sales(TTM) 9.41 | ||
Enterprise Value to Revenue 2.7 | Enterprise Value to EBITDA 110.81 | Shares Outstanding 251.20M | Shares Floating 108.79M |
Shares Outstanding 251.20M | Shares Floating 108.79M | ||
Percent Insiders 57.36 | Percent Institutions 20.43 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About BioNTech SE
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2019-10-10 | Co-Founder, CEO & Chair of the Management Board Dr. Ugur Sahin M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7807 | Website https://www.biontech.de |
Full time employees 7807 | Website https://www.biontech.de | ||
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.